Investing.com -- Wellgistics Health Inc (NASDAQ:WGRX) stock surged 9.2% on Monday after the health information technology company announced the commercial launch of diabetes prescription drug ...

Launch targets $16 billion SGLT-2 inhibitor market that serves 33 million type II diabetics in the US, many of whom are ...

A new study shows that older adults with type 2 diabetes who start treatment with sodium–glucose cotransporter-2 (SGLT-2) ...

A new study shows that older adults with type 2 diabetes who start treatment with sodium–glucose cotransporter-2 (SGLT-2) ...

Lexicon Pharmaceuticals, Inc. currently offers three late-stage assets Zynquista, Inpefa & Pilavapadin. Learn more about LXRX ...

Patients with type 2 diabetes who received sodium-glucose cotransporter-2 inhibitors had a lower risk for rheumatic disease ...

You know them as Flo, the Progressive Insurance saleswoman; Mayhem, the human embodiment of disasters covered by Allstate; and the unstoppable dancer from the Jardiance diabetes drug ads.

Launch targets $16 billion SGLT-2 inhibitor market that serves 33 million type II diabetics in the US, many of whom are uninsured and underinsured and whose out-of-pocket costs exceed Brenzavvy's cash ...

President Joe Biden speaks about his administration's plans to protect Social Security and Medicare and lower health care costs, Feb. 9, 2023, at the University of Tampa in Tampa, Fla. (AP ...